Free tool
FAERS Monitor: Promacta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022291 or its brand name (Promacta, Eltrombopag Olamine). Reports on generic versions are filed under their own applications.
Reports
19,469
Serious
11,673
60% of reports
Hospitalization
4,283
Death reported
4,302
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- platelet count decreased3,722
- death3,223
- drug ineffective1,482
- platelet count increased1,069
- fatigue1,054
- headache884
- nausea756
- diarrhoea738
- malaise567
- off label use525
- product use in unapproved indication513
- asthenia485
- dizziness467
- contusion449
- pyrexia443
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 118 |
| 2010 | 414 |
| 2011 | 674 |
| 2012 | 316 |
| 2013 | 348 |
| 2014 | 513 |
| 2015 | 1,142 |
| 2016 | 707 |
| 2017 | 979 |
| 2018 | 1,126 |
| 2019 | 1,590 |
| 2020 | 1,736 |
| 2021 | 2,198 |
| 2022 | 2,750 |
| 2023 | 2,407 |
| 2024 | 1,235 |
| 2025 | 802 |
| 2026 | 414 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,690 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| platelet count increasedSignal | 1,069 | 96.4 | 90.7 | 92,634 |
| platelet count decreasedSignal | 3,722 | 39.1 | 37.9 | 133,835 |
| contusionSignal | 449 | 5.1 | 4.6 | 1,457 |
| deathSignal | 3,223 | 4.1 | 3.9 | 7,697 |
| product use in unapproved indicationSignal | 513 | 2.2 | 2.1 | 354 |
| headache | 884 | 1.5 | 1.4 | 163 |
| fatigue | 1,054 | 1.5 | 1.4 | 160 |
| malaise | 567 | 1.4 | 1.3 | 65 |
| asthenia | 485 | 1.4 | 1.3 | 55 |
| pyrexia | 443 | 1.4 | 1.3 | 47 |
| diarrhoea | 738 | 1.2 | 1.2 | 34 |
| drug ineffective | 1,482 | 1.2 | 1.2 | 60 |
| nausea | 756 | 1.0 | 1.0 | 1 |
| dizziness | 467 | 1.0 | 0.9 | 0 |
| off label use | 525 | 0.6 | 0.6 | 105 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.